Edito
Author:
Dr. Claire Labreveux - Director of the R&D Department of Unicancer
Unicancer, a pioneer in personalized medicine, has developed for several years, as part of its research strategy, a research program on circulating tumor DNA.
Author:
French Breast Cancer Intergroup Unicancer
PADA-1 trial : changing hormone therapy following early detection of ESR1 mutations can delay the onset of cancer resistance to standard therapy.
Author:
Nicholas Turner, The Institute of Cancer Research (UK)
TRAK-ER: potential benefits of molecular relapse monitoring with ctDNA assays in patients with ER positive HER2 negative breast cancer on adjuvant endocrine therapy.
Author:
Unicancer - UCGI group
PANIRINOX : evaluating FOLFIRINOX + Panitumumab vs mFOLFOX6 + Panitumumab in patients with unresectable metastatic colorectal cancer B-RAF and RAS wild type.
Author:
Unicancer, Radiation oncology Group, UNITRAD
NIRVANA-Lung: evaluate predictive biomarker of overall survival in patients with advanced non-small cell lung cancer
Author:
Gustave Roussy
REVEAL: Reshape the EValuation Efficiency and Accuracy of non-small cell Lung cancer
Author:
Dr. Gudrun Schleiermacher, pediatrician and researcher at Institut Curie
A blood test to diagnose eye cancer in children
Author:
Dr Esma SAADA, Medical Oncologist - Centre Antoine Lacassagne, Nice
TARGET: Added value of liquid biopsy to tumour screening performed in the Molecular Tumour
Author:
ICM and IRCM, Montpellier
Circulating DNA research and applications : a synergistic effort by the ICM and the IRCM in Montpellier
